메뉴 건너뛰기




Volumn 55, Issue 14, 1999, Pages 4315-4324

Asymmetric synthesis of seven-carbon segments of the phorboxazoles and (-)-discodermolide: Complementary route from racemic trans-2,4-dimethyl-8- oxabicyclo[3.2.1]oct-6-en-3-one

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID ETHYL ESTER; BENZOPHENONE DERIVATIVE; BICYCLO[3.2.1]OCTANE DERIVATIVE; BICYCLO[3.3.1]NONANE DERIVATIVE; DISCODERMOLIDE; LACTONE DERIVATIVE; NATURAL PRODUCT; OXAZOLE DERIVATIVE; PHORBOXAZOLE A; PHORBOXAZOLE B; TERT BUTYL METHYL ETHER; TETRAHYDROPYRAN DERIVATIVE; UNCLASSIFIED DRUG;

EID: 0033118794     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4020(99)00127-1     Document Type: Article
Times cited : (68)

References (48)
  • 37
    • 0013536342 scopus 로고    scopus 로고
    • note
    • Basic equilibration (DBU, DCM or MeOH, MeONa) of 2α,4α-dimethyl-8-oxabicyclo[3.2.1]oct-6-en-3-one gave the epimers in a ratio of 2α,4α:2α,4β = 1.6:1 These were not separable by conventional means.
  • 38
    • 0032935559 scopus 로고    scopus 로고
    • note
    • 2-promoted reduction of oxabicyclic ketone rac-2 furnishes 2α-methyl-8-oxabicyclo[3.2.1]oct-6-en-3-one rac-14, a precursor of tetrahydropyran units of spongistatin and lasonolide. (Formula Presented) For the [4+3] cycloaddition of α,α-dimethoxysilyl enol ethers to dienes see also: Pierau, S.; Hoffmann, H. M.R. Synlett, 1999, 213.
  • 39
    • 0032935559 scopus 로고    scopus 로고
    • For the [4+3] cycloaddition of α,α-dimethoxysilyl enol ethers to dienes see also
    • 2-promoted reduction of oxabicyclic ketone rac-2 furnishes 2α-methyl-8-oxabicyclo[3.2.1]oct-6-en-3-one rac-14, a precursor of tetrahydropyran units of spongistatin and lasonolide. (Formula Presented) For the [4+3] cycloaddition of α,α-dimethoxysilyl enol ethers to dienes see also: Pierau, S.; Hoffmann, H. M.R. Synlett, 1999, 213.
    • (1999) Synlett , pp. 213
    • Pierau, S.1    Hoffmann, H.M.R.2
  • 43
    • 0002232935 scopus 로고    scopus 로고
    • A "racemic switch" has been defined as the redevelopment in single-enantiomer form of a drug that was first approved as a racemate; see: September 21, In our case the early racemic switch provides two key single-isomer precursors of structurally different bioactive natural products
    • A "racemic switch" has been defined as the redevelopment in single-enantiomer form of a drug that was first approved as a racemate; see: Stinson, S. C. Chem. Eng. News 1998, September 21, 83-104. In our case the early racemic switch provides two key single-isomer precursors of structurally different bioactive natural products.
    • (1998) Chem. Eng. News , pp. 83-104
    • Stinson, S.C.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.